Explore / Peer-reviewed article
Peer-reviewed articleOpen access

Increasing dose of esketamine for supplemental analgesia after complex spinal fusion surgery: a randomized and double-blind trial.

Guo ZM, Cui F, Zhang Y, Ma JH, Wang DX

BMC anesthesiologyJun 2, 2026License: open accessChina, United States0 citationsDOI: 10.1186/s12871-026-03962-1

Abstract

<h4>Background</h4>Complex spinal surgery is associated with significant trauma and pain. Herein we tested the hypothesis that increasing the dose of esketamine, as a supplement to patient-controlled analgesia, might improve pain relief after extensive spinal surgery.<h4>Methods</h4>In this randomized, double-blind, and controlled trial, we enrolled adults who were scheduled to undergo extensive posterior spinal fusion. Participants were randomized in a 1:1:1 ratio to receive patient-controlled sufentanil-dexmedetomidine analgesia supplemented with esketamine at 0.25 (Esk25), 0.5 (Esk50), or 0.75 (Esk75) mg/ml. Our primary endpoint was an integrated index of pain intensity and opioid consumption (ranging from - 200% to + 200%, with higher scores indicating greater pain and/or more opioid consumption) with movement within 72 h after surgery.<h4>Results</h4>A total of 312 patients (median 38 years; 24.4% female) were enrolled and randomized; all were included in the intention-to-treat analysis. The primary endpoint did not differ among three groups (Esk50 vs. Esk25: mean difference - 2 [95% CI -31 to 28]; Esk75 vs. Esk25: mean difference 13 [95% CI -16 to 43]. The proportions reporting nausea/vomiting and nausea were higher in the Esk75 group than in the Esk25 group (nausea/vomiting: 70.2% [73/104] with Esk75 vs. 52.9% [55/104] with Esk25; P = 0.021; nausea: 68.3% [71/104] with Esk75 vs. 49.0% [51/104] with Esk25; P = 0.005).<h4>Conclusions</h4>For adult patients recovering from extensive posterior spinal fusion, increasing esketamine concentration in patient-controlled analgesia from 0.25 to 0.5 and 0.75 mg/ml did not improve pain relief or reduce opioid consumption. Esketamine at a concentration of 0.75 mg/ml increased postoperative nausea and vomiting.<h4>Trial registration</h4>ClinicalTrials.gov, NCT06062550; first submitted on September 25, 2023.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetaminePTSDPain

Keywords

Patient-controlled AnalgesiaDexmedetomidinesufentanilPerioperative AnalgesiaEsketamineExtensive Spinal Fusion

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.